(2S)-N-[(3S)-6-(carbamoylamino)-2-oxohexan-3-yl]-3-methyl-2-(methylamino)butanamide

• 分子结构分类: 有机化合物 - 有机酸及其衍生物 - 羧酸及其衍生物
• 英文名称: (2S)-N-[(3S)-6-(carbamoylamino)-2-oxohexan-3-yl]-3-methyl-2-(methylamino)butanamide
• 化学式: C₁₃H₂₆N₄O₃
• 分子量: 286.37
• InChiKey: CEKBIZXSKXIHKR-QWRGUYRKSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.2
• 重原子数：
  20
• 可旋转键数：
  9
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.77
• 拓扑面积：
  113
• 氢给体数：
  4
• 氢受体数：
  4

文献信息

• [EN] LYMPHATIC SYSTEM-DIRECTING LIPID PRODRUGS<br/>[FR] PROMÉDICAMENTS LIPIDIQUES ORIENTANT VERS LE SYSTÈME LYMPHATIQUE
  申请人：ARIYA THERAPEUTICS INC

  公开号：WO2019046491A1

  公开（公告）日：2019-03-07

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a provided lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，其制药组合物，制备这种前药和组合物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法，包括向需要的患者施用所提供的脂质前药或其制药组合物。
• [EN] ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER<br/>[FR] CONJUGUÉ ANTICORPS-MÉDICAMENT ET SON UTILISATION POUR LE TRAITEMENT DU CANCER
  申请人：PF MEDICAMENT

  公开号：WO2015162293A1

  公开（公告）日：2015-10-29

  The present invention relates to an antibody-drug-conjugate. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to a Target, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug-conjugate for the treatment of cancer.

  本发明涉及一种抗体药物偶联物。从一方面来说，该发明涉及一种抗体药物偶联物，包括一种能够与靶标结合的抗体，所述抗体与至少一种选自多拉司汀10衍生物和奥里司汀衍生物的药物偶联。该发明还包括治疗方法以及使用所述抗体药物偶联物治疗癌症的应用。
• [EN] COMPOSITION FOR THE TREATMENT OF IGF-1R EXPRESSING CANCER<br/>[FR] COMPOSITION POUR LE TRAITEMENT D'UN CANCER EXPRIMANT IGF-1R
  申请人：PF MEDICAMENT

  公开号：WO2017072196A1

  公开（公告）日：2017-05-04

  The present invention relates to a method for the treatment of IGF-IR expressing cancers as well as to a compositions and a kit for said traitment. From one aspect, the invention reates to the combined use of a first antibody for the determination of the IGF-IR status of a cancer and a second antibody used as an ADC for the treatment of said cancer.

  本发明涉及一种用于治疗表达IGF-IR的癌症的方法，以及用于所述治疗的组合物和试剂盒。从一方面来说，发明涉及第一抗体用于确定癌症的IGF-IR状态和第二抗体作为ADC用于治疗所述癌症的联合使用。
• [EN] LIPID PRODRUGS OF PREGNANE NEUROSTEROIDS AND USES THEREOF<br/>[FR] PROMÉDICAMENTS LIPIDIQUES DE NEUROSTÉROÏDES DE PRÉGNANE ET LEURS UTILISATIONS
  申请人：PURETECH HEALTH LLC

  公开号：WO2020028787A1

  公开（公告）日：2020-02-06

  The present invention provides lymphatic system-directing lipid prodrugs, pharmaceutical compositions thereof, methods of producing such prodrugs and compositions, as well as methods of improving the bioavailability or other properties of a therapeutic agent that comprises part of the lipid prodrug. The present invention also provides methods of treating a disease, disorder, or condition such as those disclosed herein, comprising administering to a patient in need thereof a disclosed lipid prodrug or a pharmaceutical composition thereof.

  本发明提供了淋巴系统定向脂质前药，以及其制药组合物、生产这种前药和组合物的方法，以及改善作为脂质前药一部分的治疗剂的生物利用度或其他性质的方法。本发明还提供了治疗疾病、紊乱或症状的方法，包括向需要的患者施用所述的脂质前药或其制药组合物。
• [EN] IGF-1R ANTIBODY-DRUG-CONJUGATE AND ITS USE FOR THE TREATMENT OF CANCER<br/>[FR] CONJUGUÉ ANTICORPS DE L'IGF-1R-MÉDICAMENT ET SON UTILISATION POUR LE TRAITEMENT DU CANCER
  申请人：PF MEDICAMENT

  公开号：WO2015162291A1

  公开（公告）日：2015-10-29

  The present invention relates to an antibody-drug-conjugate capable of binding IGF-1R. From one aspect, the invention relates to an antibody-drug-conjugate comprising an antibody capable of binding to IGF-1R, said antibody being conjugated to at least one drug selected from derivatives of dolastatin 10 and auristatins. The invention also comprises method of treatment and the use of said antibody-drug- conjugate for the treatment of cancer.

  本发明涉及一种能够结合IGF-1R的抗体药物偶联物。从一方面来说，该发明涉及一种抗体药物偶联物，包括一种能够结合IGF-1R的抗体，所述抗体与至少一种选自多拉司汀10衍生物和奥里司汀衍生物的药物偶联。该发明还包括治疗方法以及使用所述抗体药物偶联物治疗癌症的方法。